Aurora Cannabis (ACB, Financial) experienced a significant stock movement with a sharp decline of 5.29%. Trading at $4.48 per share, the company saw a volume turnover of 636,584 shares with a turnover rate of 1.16% and a price fluctuation of 5.22%.
Recent financial results revealed that Aurora Cannabis reported a revenue of $59.47 million, a net profit of $1.91 million, and earnings per share of -$0.16. The gross profit stood at $586,521.99, with a price-to-earnings ratio of -6.92.
In terms of analyst ratings, 17% of the six participating institutions recommended a "buy," while 83% advised to "hold," with no "sell" recommendations.
Within the pharmaceutical industry, Aurora Cannabis's sector experienced a modest decline of 0.15%. Comparatively, stocks such as Cyclo Therapeutics Inc and Im Cannabis Corp saw significant gains, while Evoke Pharma, Inc. and others were more active.
Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells both medical and recreational cannabis through a variety of brands. Although primarily operating in Canada, the company has expanded into over 20 countries through medical cannabis export agreements and cultivation facilities.
